Suven Pharma acquires 67.5% stake in Sapala Organics for $27.5 million, targeting the fast-growing $750M oligonucleotide market.
Suven Pharma, a leading Indian CDMO, is acquiring a 67.5% stake in Hyderabad-based Sapala Organics for Rs 229.5 crore ($27.5 million). Suven expects to complete the acquisition of the remaining stake in Sapala after FY2026-27, subject to closing conditions. Sapala Organics has a presence in the fast-growing oligonucleotide and nucleic acid building blocks segment, which has a $750 million market size and a 20% CAGR.
June 13, 2024
4 Articles